Gaming the System: Orphan Drugs Part 3

The video discusses how drug manufacturers exploit the Orphan Drug Act by recycling existing drugs, marketing them for unapproved uses, and using salami slicing to extend market exclusivity. These practices undermine the act's intent to encourage novel research for rare diseases. The video highlights the need for regulatory changes to prevent such exploitation.

What new insight or understanding did you gain from this video?